MAXIM PHARMACEUTICALS TO HOST CONFERENCE CALL
- Review of AML Data Presented at ASH to be Provided -
SAN DIEGO, December 2, 2004 – Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced it will hold a conference call on Tuesday, December 7, 2004 at 10:00 a.m. EST (7:00 a.m. PST or 4:00 p.m. CET). Larry Stambaugh, Chairman and Chief Executive Officer of Maxim, will discuss the results of Maxim’s Phase 3 clinical trial for Ceplene™ in the treatment of acute myeloid leukemia patients in complete remission as presented on December 6, 2004 at the 46th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA. To access the live conference call, U.S. participants may dial (888) 202-2422 and international participants may dial (913) 981-5592. An audio replay will be available for 2 days following the conclusion of the call. To access this replay, U.S. participants may dial (888) 203-1112 and international participants may dial (719) 457-0820. Please reference access code 901176 for the live and recorded conference call. This conference call will also be webcast live and archived on Maxim’s website at http://www.maxim.com. Please log onto Maxim’s website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary. Maxim Overview Maxim Pharmaceuticals is a global biopharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers and liver diseases. Maxim's research and development programs are designed to offer hope to patients by developing safe and effective therapeutic candidates that have the potential to extend survival while maintaining quality of life. Ceplene, Maxim's lead drug candidate, is an immune-modulator that reverses immune suppression and protects critical immune cells. Because Ceplene modifies basic immune functions, it has the potential to be used in a range of diseases. Additionally, Maxim is developing small-molecule apoptosis modulators for cancer, cardiovascular disease and degenerative diseases. Ceplene and the apoptosis compounds are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the efficacy, safety and intended utilization of Ceplene, the conduct and results of the Company's clinical trials, and the Company’s plans regarding regulatory filings, future research and clinical trials. Such statements are only predictions and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger-scale or later clinical trials, the risk that the Company will not obtain approval to market its products, and the risks associated with the Company’s reliance on outside financing to meet its capital requirements. These factors and others are more fully discussed in the Company's periodic reports and other filings with the Securities and Exchange Commission.